Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia

被引：2
|
作者：
Piccaluga, PP
Malagola, M
Rondoni, M
Amabile, M
Paolini, S
Soverini, S
Gaitani, S
Visani, G
Baccarani, M
Martinelli, G
机构：
[1] Univ Bologna, Inst Haematol & Med Oncol L&A Seragnoli, Bologna, Italy
[2] S Salvatore Hosp, Dept Haematol, Pesaro, Italy
来源：
EUROPEAN JOURNAL OF HAEMATOLOGY | 2004年 / 72卷 / 04期
关键词：
D O I：
10.1111/j.1600-0609.2004.00212.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：302 / 303
页数：2
相关论文
共 47 条
  • [31] THE IMMUNOMODULATORY AGENT FTY720 INDUCES APOPTOSIS AND INHIBITS GROWTH OF BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA CELLS AND OVERCOMES IMATINIB RESISTANCE IN VITRO
    Schmidt-Tanguy, A.
    Badura, S.
    Nijmeijer, B. A.
    Wystub, S.
    Romanski, A.
    Ottmann, O. G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 249 - 250
  • [32] Leptomycin B overcomes imatinib resistance mediated by stromal cells and mutant BCR-ABL in Philadelphia chromosome-positive acute lymphoblastic leukemia cells.
    Tojo, A
    Izawa, K
    Sekine, R
    Nagamura, T
    Yoshida, M
    Tsuji, T
    BLOOD, 2004, 104 (11) : 575A - 575A
  • [33] Pattern and evolution of BCR-ABL kinase domain mutations in patients with Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL) developing resistance to imatinib.
    Pfeifer, H
    Wassmann, B
    Pavlova, A
    Mueller, M
    Wunderle, L
    Brueck, P
    Oldenburg, J
    Hochhaus, A
    Gschaidmeier, H
    Hoelzer, D
    Ottmann, OG
    BLOOD, 2005, 106 (11) : 46A - 47A
  • [34] Efficacy of imatinib mesylate (STI571) in conjunction with alpha-interferon: long-term quantitative molecular remission in relapsed P-190BCR-ABL-positive acute lymphoblastic leukemia
    G Visani
    A Isidori
    M Malagola
    D Alberti
    R Capdeville
    G Martinelli
    PP Piccaluga
    M Amabile
    B Guiducci
    S Tura
    M Baccarani
    Leukemia, 2002, 16 : 2159 - 2160
  • [35] Efficacy of imatinib mesylate (STI571) in conjunction with alpha-interferon:: long-term quantitative molecular remission in relapsed P-190BCR-ABL-positive acute lymphoblastic leukemia
    Visani, G
    Isidori, A
    Malagola, M
    Alberti, D
    Capdeville, R
    Martinelli, G
    Piccaluga, PP
    Amabile, M
    Guiducci, B
    Tura, S
    Baccarani, M
    LEUKEMIA, 2002, 16 (10) : 2159 - 2160
  • [36] Drug Resistance and BCR-ABL Kinase Domain Mutations in Philadelphia Chromosome- Positive Acute Lymphoblastic Leukemia From the Imatinib to the Second- Generation Tyrosine Kinase Inhibitor Era
    Soverini, Simona
    De Benedittis, Caterina
    Papayannidis, Cristina
    Paolini, Stefania
    Venturi, Claudia
    Iacobucci, Ilaria
    Luppi, Mario
    Bresciani, Paola
    Salvucci, Marzia
    Russo, Domenico
    Sica, Simona
    Orlandi, Ester
    Intermesoli, Tamara
    Gozzini, Antonella
    Bonifacio, Massimiliano
    Rigolin, Gian Matteo
    Pane, Fabrizio
    Baccarani, Michele
    Cavo, Michele
    Martinelli, Giovanni
    CANCER, 2014, 120 (07) : 1002 - 1009
  • [37] BCR-ABL-independent and RAS/MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4
    Suzuki, Momoko
    Abe, Akihiro
    Imagama, Shizuka
    Nomura, Yuka
    Tanizaki, Ryohei
    Minami, Yosuke
    Hayakawa, Fumihiko
    Ito, Yoshie
    Katsumi, Akira
    Yamamoto, Kazuhito
    Emi, Nobuhiko
    Kiyoi, Hitoshi
    Naoe, Tomoki
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 84 (03) : 229 - 238
  • [38] Adaptive autocrine secretion of the granulocyte macrophage colony stimulating factor (GM-CSF) mediates imatinib- and nilotinib-resistance in BCR/ABL-positive progenitors via JAK-2/STAT-5 pathway activation.
    Burchert, Andreas
    Wang, Ying
    Brendel, Cornelia
    Erben, Philipp
    Manley, Paul W.
    Hochhaus, Andreas
    Cai, Dali
    Neubauer, Andreas
    BLOOD, 2006, 108 (11) : 620A - 620A
  • [39] Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin
    Nimmanapalli, R
    O'Bryan, E
    Huang, M
    Bali, P
    Burnette, PK
    Loughran, T
    Tepperberg, J
    Jove, R
    Bhalla, K
    CANCER RESEARCH, 2002, 62 (20) : 5761 - 5769
  • [40] High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia
    Rea, D
    Legros, L
    Raffoux, E
    Thomas, X
    Turlure, P
    Maury, S
    Dupriez, B
    Pigneux, A
    Choufi, B
    Reman, O
    Stéphane, D
    Royer, B
    Vigier, M
    Ojeda-Uribe, M
    Recher, C
    Dombret, H
    Huguet, F
    Rousselot, P
    LEUKEMIA, 2006, 20 (03) : 400 - 403
12345